ArticleJournal of immunology (Baltimore, Md. : 1950)2022

Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy.

Melissa G Lechner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.